<?xml version="1.0" encoding="UTF-8"?>

<?xml-stylesheet type="text/xsl" href="/static/oaitohtml.xsl"?>

<!--
<?xml-stylesheet type="text/xsl" href="/oaitohtml.xsl"?>
-->

<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <responseDate>2026-10-11T20:54:52Z</responseDate>
    <request verb="GetRecord" metadataPrefix="oai_dc" identifier="10.57760/sciencedb.34654" >https://www.scidb.cn/oai</request>
<GetRecord>
    <record>
    <header >
    <identifier>10.57760/sciencedb.34654</identifier>
    <datestamp>2026-08-21T17:13:59Z</datestamp>
</header>
    <metadata>
        
<oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:date>2026-08-21</dc:date>
  <dc:title>A bivalent recombinant protein vaccine based on type I feline coronavirus spike and feline parvovirus VP2 reduces disease and viral shedding after challenge in cats</dc:title>
  <dc:identifier>doi:10.57760/sciencedb.34654</dc:identifier>
  <dc:language>en</dc:language>
  <dc:description>Feline coronavirus (FCoV) and feline parvovirus (FPV) are two highly pathogenic viruses that pose major threats to feline populations. In this research, we describe&amp;nbsp;for the first time the development of a bivalent recombinant protein targeting the FCoV-I S and FPV VP2 antigens using the Bac-to-Bac baculovirus expression system. ELISA results demonstrated that the bivalent recombinant&amp;nbsp;protein elicited robust, antigen-specific antibody responses against both FCoV S and FPV VP2 proteins in mice. Flow cytometry further revealed significantly elevated IFN-&amp;gamma; secretion in splenocytes from immunized mice, indicating a strong cellular immune response. In challenge experiments, the bivalent protein conferred complete protection against both FCoV and FPV.&amp;nbsp;These results demonstrate that the bivalent recombinant protein provides strong humoral and cellular immune protection and effectively prevents FCoV-I and FPV infection. This candidate vaccine shows considerable potential for further development in feline disease prevention.</dc:description>
  <dc:subject>challenge protection experiment; antibody level; recombinant protein; FCoV; FPV</dc:subject>
  <dc:creator>Ma Yuanzhen</dc:creator>
  <dc:rights>PUBLIC</dc:rights>
  <dc:rights>https://creativecommons.org/publicdomain/zero/1.0/</dc:rights>
  <dc:type>dataset</dc:type>
  <dc:publisher>Science Data Bank</dc:publisher>
</oai_dc:dc>

    </metadata>
</record>
</GetRecord>
</OAI-PMH>